Sign Out
Dayvus is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus (T2DM): as monotherapy; in dual combination with metformin, when diet, exercise and metformin alone do not result in adequate glycemic control, with sulfonylurea (SU), when diet, exercise and SU alone do not result in adequate glycemic control, with a thiazolidinedione (TZD) when diet, exercise and TZD alone do not result in adequate glycemic control; in triple combination with a sulfonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycemic control.
Dayvus is also indicated in combination with insulin (with or without metformin) when diet, exercise, and a stable dose of insulin do not result in adequate glycemic control.
Dayvus is also indicated as initial combination therapy with metformin in patients with T2DM whose diabetes is not adequately controlled by diet and exercise alone.
Continue with Google